ANTERIS TECHNOLOGIES LTD (AVR)

The suspension of trading in the securities of Anteris Technologies Global Corp. will be lifted on the commencement of trading following implementation of the schemes of arrangement between Anteris Technologies Limited, its shareholders, its optionholders and Anteris Technologies Global Corp. under Part 5.1 of the Corporations Act 2001 (Cth).

The company has implemented share and option schemes to redomiciliate its subsidiaries and ATL to the United States. All ATL shares have been transferred to Anteris Technologies Global Corp., with ATGC becoming the only shareholder. A total of 21,139,816 ATGC Shares were issued, with holding statements expected on 18 December 2024. All ATL options have been cancelled and exchanged for ATGC options.

The company releases a prospectus for an offer of 14,800,000 shares of common stock, with a par value of $0.0001 per share, at an initial public offering price of $6.00 per share.

The company releases a prospectus for an offer of 14,800,000 shares of common stock, with a par value of $0.0001 per share, at an initial public offering price of $6.00 per share.

The company lodges its IPO Roadshow Presentation.

The company lodges its Daily Stabilisation Activity Report.

The company lodges the following: Appendix 1A, Information Form and Checklist, Information Form and Checklist Annexure 3, Scheme Booklet, Supplementary Scheme Booklet, Amended and Restated Bylaws, Trading Policy, Corporate Governance Statement, Equity Incentive Plan, and Pre-Quotation Disclosure.

On 4 December 2024 ATL announced that the Supreme Court of Queensland granted orders approving the Schemes. On 5 December 2024 ATL announced that the Schemes were now legally effective and ATL's shares were suspended from trading on ASX from the close of trade. On 13 December 2024 ATL announced that the conditions of the Schemes have been satisfied. ATGC will be admitted to the official list of ASX today, 16 December 2024.

The company has announced its initial public offering of 14,800,000 shares of its common stock in the U.S. at an initial price of $6.00 per share. The shares are expected to begin trading on the Nasdaq Global Market on December 13, 2024, and close on December 16, 2024. The net proceeds will be used for the development of its DurAVR® transcatheter heart valve and a randomized global pivotal study for treating severe aortic stenosis.

The company confirms the implementation timetable for its Holdco IPO, confirming that the Condition Subsequent to the Schemes has been satisfied.

The company has launched its initial public offering of 14,800,000 shares of its common stock in the U.S. The offering will be offered by ATGC, with underwriters having a 30-day option to purchase up to an additional 2,220,000 shares at the initial public offering price. The net proceeds will be used for the development of its DurAVR® transcatheter heart valve and a randomized global pivotal study for treating severe aortic stenosis.

The company's securities will be suspended from quotation on 5 December 2024 to implement share and option schemes. Anteris Technologies Global Corp. will acquire 100% of AVR's shares, becoming the new ultimate parent company of ATL and the Anteris Group, effectively redomiciling AVR to the US.

The suspension of trading in the securities of Anteris Technologies Ltd will be lifted immediately following the release by AVR of an announcement regarding a capital raising.

The company releases a notice of proposed issue of securities.

The company has raised $40 million with the issue of two million new ordinary shares at $20 per new share. The funds will be used for preparation for the FDA Pivotal trial of the Company's DurAVRâ„¢ THV for treating severe aortic stenosis, continued Valve-in-Valve trials and general working capital expenses. The Placement will settle in two tranches of $33.8m on 1 November 2023 and a second tranche of $6.2m anticipated for 15 November 2023.

Anteris reports unprecedented positive hemodynamic results from the Interim Analysis of its US-EFS Trial for DurAVRTM THV.

The securities of Anteris Technologies Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of AVR, pending the release of an announcement regarding capital raising.

The suspension of trading in the securities of Anteris Technologies Ltd will be lifted immediately, following the release by AVR of an announcement regarding a proposed capital package.

The company issues a notice of Proposed issue of Securities - AVR.

$20M in a funding package principally for the Company's TAVR research and development including general working capital expenses. Facility provided by Mercer Street Global Opportunity Fund, LLC, a New York based investment fund.

The company has entered into a short-term facility for the advance of $1,220,000 that provides the company with immediate funds equivalent to its forecasted research and development tax incentive offset for the majority of the 2020 calendar year.

The company releases an Appendix 2A.

1.1M raised in a placement to sophisticated investors at $3.37 per share "“ 10% discount to the last closing share price. Provides working capital as Anteris continues to demonstrate superior performance of the DurAVRâ„¢, 3D single-piece, aortic valve.

The securities of Anteris Technologies Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of AVR, pending the release of an announcement regarding a proposed capital package.

name changed from Admedus Ltd